Talazoparib Add-On Improves Outcomes in Metastatic Prostate

For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.

Related Keywords

Pennsylvania , United States , Canada , Fox Chase Cancer Center , Spain , Philadelphia , America , Astellas Pharma , Neeraj Agarwal , Selena Castro , Matthew Zibelman , Bristol Myers Squibb , Roche Zibelman , Huntsman Cancer Institute , University Of Utah , Novartis , Genitourinary Oncology Program , Pfizer , Astrazeneca , Serono , Department Of Hematology Oncology , Genitourinary Cancers Symposium , Instituto De Investigaci , South America , Adverse Events , Clovis Oncology , Cancers Symposium , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Breast Cancer , Alignant Breast Neoplasm , Cancer , Alignant Neoplasia , Arcinoma , Prostatic , Biologic Therapy , Genomics , Genomic Medicine , Edicine Genomic , Prostate Specific Antigen Psa , Prostate Specific Antigen , Sa , Tumor , Parp Inhibitors , Parp Inhibition , Oly Adp Ribose Polymerase Inhibitor , Myelodysplastic Syndr ,